6.
Takayama K, Misawa A, Suzuki T, Takagi K, Hayashizaki Y, Fujimura T
. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun. 2015; 6:8219.
DOI: 10.1038/ncomms9219.
View
7.
Misawa A, Takayama K, Urano T, Inoue S
. Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells. J Biol Chem. 2016; 291(34):17861-80.
PMC: 5016176.
DOI: 10.1074/jbc.M116.718536.
View
8.
Meng D, Yang S, Wan X, Zhang Y, Huang W, Zhao P
. A transcriptional target of androgen receptor, miR-421 regulates proliferation and metabolism of prostate cancer cells. Int J Biochem Cell Biol. 2016; 73:30-40.
DOI: 10.1016/j.biocel.2016.01.018.
View
9.
Yap K, Li S, Munoz-Cabello A, Raguz S, Zeng L, Mujtaba S
. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell. 2010; 38(5):662-74.
PMC: 2886305.
DOI: 10.1016/j.molcel.2010.03.021.
View
10.
Clinckemalie L, Vanderschueren D, Boonen S, Claessens F
. The hinge region in androgen receptor control. Mol Cell Endocrinol. 2012; 358(1):1-8.
DOI: 10.1016/j.mce.2012.02.019.
View
11.
Emmrich S, Putzer B
. Checks and balances: E2F-microRNA crosstalk in cancer control. Cell Cycle. 2010; 9(13):2555-67.
DOI: 10.4161/cc.9.13.12061.
View
12.
Nozawa R, Yamamoto T, Takahashi M, Tachiwana H, Maruyama R, Hirota T
. Nuclear microenvironment in cancer: Control through liquid-liquid phase separation. Cancer Sci. 2020; 111(9):3155-3163.
PMC: 7469853.
DOI: 10.1111/cas.14551.
View
13.
Leyten G, Hessels D, Jannink S, Smit F, de Jong H, Cornel E
. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2012; 65(3):534-42.
DOI: 10.1016/j.eururo.2012.11.014.
View
14.
Lin Q, Cai J, Wang Q
. The Significance of Circular RNA DDX17 in Prostate Cancer. Biomed Res Int. 2020; 2020:1878431.
PMC: 7456467.
DOI: 10.1155/2020/1878431.
View
15.
Zhou Y, Yang H, Xia W, Cui L, Xu R, Lu H
. LncRNA MEG3 inhibits the progression of prostate cancer by facilitating H3K27 trimethylation of EN2 through binding to EZH2. J Biochem. 2019; 167(3):295-301.
DOI: 10.1093/jb/mvz097.
View
16.
Abbas A, Gupta S
. The role of histone deacetylases in prostate cancer. Epigenetics. 2008; 3(6):300-9.
PMC: 2683066.
DOI: 10.4161/epi.3.6.7273.
View
17.
Fletcher C, Sulpice E, Combe S, Shibakawa A, Leach D, Hamilton M
. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene. 2019; 38(28):5700-5724.
PMC: 6755970.
DOI: 10.1038/s41388-019-0823-5.
View
18.
Moilanen A, Poukka H, Karvonen U, Hakli M, Janne O, Palvimo J
. Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription. Mol Cell Biol. 1998; 18(9):5128-39.
PMC: 109098.
DOI: 10.1128/MCB.18.9.5128.
View
19.
Wei J, Huang K, Yang C, Kang C
. Non-coding RNAs as regulators in epigenetics (Review). Oncol Rep. 2016; 37(1):3-9.
DOI: 10.3892/or.2016.5236.
View
20.
Majid S, Dar A, Saini S, Shahryari V, Arora S, Zaman M
. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res. 2012; 19(1):73-84.
PMC: 3910324.
DOI: 10.1158/1078-0432.CCR-12-2952.
View